학술논문

The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B‐Cell Lymphoma.
Document Type
Article
Source
Oncologist; Feb2020, Vol. 25 Issue 2, pe321-e327, 7p, 1 Color Photograph, 1 Diagram, 2 Charts
Subject
B cell lymphoma
CELL receptors
IMMUNOTHERAPY
LYMPHOBLASTIC leukemia
MARKETING
T cells
DRUG approval
DISEASE remission
PANCYTOPENIA
DISEASE risk factors
Language
ISSN
10837159
Abstract
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)